Topic

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

With Sen. Bernie Sanders leading the charge on Capitol Hill, the campaign to limit U.S. outlays for prescription drugs has accelerated.

Drug Pricing Moves to Top of Legislative Agenda

Leela Barham is a freelance health economist and policy expert. She has published in peer-reviewed journals and presented at national and international conferences. She has provided advice to the Department of Health and Social Care on policy on pricing of branded medicines to inform the negotiation of a successor to the UK’s Pharmaceutical Price Regulation Scheme (PPRS), the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), as well as worked with patient groups, the NHS, pharmaceutical companies and many others internationally on the economics of healthcare and pharmaceuticals. Contact Leela on leels@btinternet.com

We all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at  similar mistakes made in the past and what can be done about them.

Minimizing the Risk of Mistakes in HTA

Christian Schuler is Senior Partner in the Life Sciences division of Simon-Kucher & Partners

Benedikt Porten is Consultant in the Life Sciences division of Simon-Kucher & Partners.

How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.

Uncovering the Potential of Advanced Analytics in International Price Management

Marc Matar is a Partner, Graham Tatham is a Partner, Rachel Rowbottom is a Director, Sam Calderwood is a Senior Consultant, and Katerina Stavri is a Consultant in 

Life Sciences division based in the company’s London office.

Post-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway. 

Project Orbis: Implications for Access and Pricing in the UK

With Democrats controlling Congress and the White House, expectations are high that policy makers will revise certain coverage and payment policies. Jill Wechsler reports.

Will Democrats Squeeze Down Drug Prices?

Ira Studin, PhD, MPH, is president of Stellar Managed Care Consulting, a pharma busines strategies firm in Cherry Hill, New Jersey. He has written Strategic Healthcare Management and numerous articles in healthcare business journals. He can be reached at istudin@stellarmc.com

How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid  an industrywide crisis.

‘Breakthrough’ Balancing Act: The Decline of the Value Proposition

Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients. 

Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part D

Ed Schoonveld is a Managing Principal at ZS Associates.

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.

Philanthropy vs. Innovation - Current Vaccine Prices: Is There a Downside?

How technology can maximize use of manufacturer copay and patient assistance programs.

Making Medication Assistance Program Solutions Work for You

Rasim Shah talks about how the application of AI to Pricing and Reimbursement can dramatically free up time spent on crunching datasets, modeling scenarios, and building price predictions.